BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 9558878)

  • 1. [Transjugular intrahepatic portosystemic shunt for the treatment of refractory ascites].
    Kanazawa H; Osada Y; Yoshimoto H; Narahara Y; Mamiya Y; Saitoh H; Matusaka S; Tada N; Kobayashi M; Kawamata H; Kumazaki T
    Nihon Shokakibyo Gakkai Zasshi; 1998 Mar; 95(3):221-9. PubMed ID: 9558878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.
    Narahara Y; Kanazawa H; Fukuda T; Matsushita Y; Harimoto H; Kidokoro H; Katakura T; Atsukawa M; Taki Y; Kimura Y; Nakatsuka K; Sakamoto C
    J Gastroenterol; 2011 Jan; 46(1):78-85. PubMed ID: 20632194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.
    Salerno F; Cammà C; Enea M; Rössle M; Wong F
    Gastroenterology; 2007 Sep; 133(3):825-34. PubMed ID: 17678653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites.
    Garcia-Tsao G
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jul; 3(7):380-9. PubMed ID: 16819501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution.
    Martinet JP; Fenyves D; Legault L; Roy L; Dufresne MP; Spahr L; Lafortune M; Pomier-Layrargues G
    Dig Dis Sci; 1997 Jan; 42(1):161-6. PubMed ID: 9009133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.
    Tan HK; James PD; Sniderman KW; Wong F
    J Gastroenterol Hepatol; 2015 Feb; 30(2):389-95. PubMed ID: 25168607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
    Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
    United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of refractory ascites.
    Williams DB; Waugh R; Selby W
    Aust N Z J Med; 1998 Oct; 28(5):620-6. PubMed ID: 9847951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
    Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
    Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of refractory ascites in a child with transjugular intrahepatic portosystemic shunt.
    Lee WS; McKiernan PJ; de Ville de Goyet JV; Tanner MS; John PR
    Acta Paediatr; 2001 Nov; 90(11):1352-5. PubMed ID: 11808914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan.
    Tsuruya K; Koizumi J; Sekiguchi Y; Ono S; Sekiguchi T; Hara T; Mishima Y; Arase Y; Hirose S; Shiraishi K; Kagawa T
    BMJ Open Gastroenterol; 2023 Apr; 10(1):. PubMed ID: 37085275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.
    Lodato F; Berzigotti A; Lisotti A; Azzaroli F; Mosconi C; Giampalma E; Renzulli M; Cappelli A; Buonfiglioli F; Calvanese C; Zoli M; Golfieri R; Mazzella G
    Scand J Gastroenterol; 2012 Dec; 47(12):1494-500. PubMed ID: 22958120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between increased colloid osmotic pressure and the resolution of refractory ascites after transjugular intrahepatic portosystemic shunt.
    Schiano TD; Black M; Hills C; Ter H; Bellary S; Miller LS
    South Med J; 2000 Mar; 93(3):305-9. PubMed ID: 10728519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites.
    Geilswijk M; Thomsen KL; Pedersen EB; Vilstrup H; Grønbæk H
    Scand J Gastroenterol; 2015 Apr; 50(4):454-61. PubMed ID: 25637473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of refractory ascites using a transjugular intrahepatic portosystemic shunt (TIPS). Clinical case].
    Zapata R; Fava M
    Rev Med Chil; 1999 Oct; 127(10):1229-35. PubMed ID: 10835740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
    Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
    Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites.
    Wong W; Liu P; Blendis L; Wong F
    Am J Med; 1999 Mar; 106(3):315-22. PubMed ID: 10190381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term efficacy of transjugular intrahepatic portosystemic shunt for the treatment of refractory ascites].
    Narahara Y; Kanazawa H; Osada Y; Yoshimoto H; Sakamoto C; Kobayashi M
    Nihon Shokakibyo Gakkai Zasshi; 2002 May; 99(5):474-82. PubMed ID: 12048890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.
    Bucsics T; Hoffman S; Grünberger J; Schoder M; Matzek W; Stadlmann A; Mandorfer M; Schwabl P; Ferlitsch A; Peck-Radosavljevic M; Trauner M; Karner J; Karnel F; Reiberger T
    Liver Int; 2018 Jun; 38(6):1036-1044. PubMed ID: 29091351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.